JP7313117B2 - 新規な使用方法 - Google Patents

新規な使用方法 Download PDF

Info

Publication number
JP7313117B2
JP7313117B2 JP2017531367A JP2017531367A JP7313117B2 JP 7313117 B2 JP7313117 B2 JP 7313117B2 JP 2017531367 A JP2017531367 A JP 2017531367A JP 2017531367 A JP2017531367 A JP 2017531367A JP 7313117 B2 JP7313117 B2 JP 7313117B2
Authority
JP
Japan
Prior art keywords
stilbene
pharmaceutical composition
dihydroxy
trans
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017531367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537936A (ja
JP2017537936A5 (cg-RX-API-DMAC7.html
Inventor
ハビエル、コテ－シエラ
スーザン、エイチ．スミス
スティーブン、エム．フレイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermavant Sciences GmbH
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of JP2017537936A publication Critical patent/JP2017537936A/ja
Publication of JP2017537936A5 publication Critical patent/JP2017537936A5/ja
Priority to JP2021086297A priority Critical patent/JP2021152018A/ja
Priority to JP2023095048A priority patent/JP2023123554A/ja
Application granted granted Critical
Publication of JP7313117B2 publication Critical patent/JP7313117B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017531367A 2014-12-12 2015-12-09 新規な使用方法 Active JP7313117B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021086297A JP2021152018A (ja) 2014-12-12 2021-05-21 新規な使用方法
JP2023095048A JP2023123554A (ja) 2014-12-12 2023-06-08 新規な使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090908P 2014-12-12 2014-12-12
US62/090,908 2014-12-12
PCT/IB2015/059490 WO2016092493A1 (en) 2014-12-12 2015-12-09 Novel method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021086297A Division JP2021152018A (ja) 2014-12-12 2021-05-21 新規な使用方法

Publications (3)

Publication Number Publication Date
JP2017537936A JP2017537936A (ja) 2017-12-21
JP2017537936A5 JP2017537936A5 (cg-RX-API-DMAC7.html) 2019-01-31
JP7313117B2 true JP7313117B2 (ja) 2023-07-24

Family

ID=55025296

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017531367A Active JP7313117B2 (ja) 2014-12-12 2015-12-09 新規な使用方法
JP2021086297A Pending JP2021152018A (ja) 2014-12-12 2021-05-21 新規な使用方法
JP2023095048A Pending JP2023123554A (ja) 2014-12-12 2023-06-08 新規な使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021086297A Pending JP2021152018A (ja) 2014-12-12 2021-05-21 新規な使用方法
JP2023095048A Pending JP2023123554A (ja) 2014-12-12 2023-06-08 新規な使用方法

Country Status (11)

Country Link
US (1) US10376475B2 (cg-RX-API-DMAC7.html)
EP (1) EP3229840B1 (cg-RX-API-DMAC7.html)
JP (3) JP7313117B2 (cg-RX-API-DMAC7.html)
KR (1) KR102607222B1 (cg-RX-API-DMAC7.html)
AR (1) AR102973A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015358910B2 (cg-RX-API-DMAC7.html)
CA (1) CA2970739C (cg-RX-API-DMAC7.html)
DK (1) DK3229840T5 (cg-RX-API-DMAC7.html)
ES (1) ES2829637T3 (cg-RX-API-DMAC7.html)
TW (1) TWI692357B (cg-RX-API-DMAC7.html)
WO (1) WO2016092493A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
CA2986251A1 (en) 2015-05-21 2016-11-24 Glaxosmithkline Intellectual Property Development Limited Topical pharmaceutical compositions
US20170231922A1 (en) * 2016-02-16 2017-08-17 Horizon GenoMed Therapeutics, Inc 3, 5-dihydroxy-4-isopropylstilbene (dhis) as miticidal agent and its therapeutic uses
CN111511357B (zh) 2017-11-10 2024-04-09 德玛万科学有限责任公司 用于制备他品洛夫的方法
US10967197B2 (en) 2018-08-29 2021-04-06 Azulite, Inc. Phototherapy devices and methods for treating truncal acne and scars
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
US20220054467A1 (en) * 2019-02-25 2022-02-24 Sol-Gel Technologies Ltd. Treatment of psoriasis with topical tapinarof-tazarotene combination compositions
US20220202737A1 (en) * 2019-03-26 2022-06-30 Sol-Gel Technologies Ltd. Treatment of hidradenitis suppurativa with tapinarof compositions
US20220287990A1 (en) * 2019-07-24 2022-09-15 Sol-Gel Technologies Ltd. Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions
US20220331268A1 (en) * 2019-09-26 2022-10-20 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
WO2021100051A1 (en) * 2019-11-24 2021-05-27 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
CN116265421B (zh) * 2021-12-17 2024-01-02 上海泽德曼医药科技有限公司 用于预防或治疗中枢神经系统相关疾病的化合物
WO2023109859A1 (zh) * 2021-12-15 2023-06-22 上海泽德曼医药科技有限公司 二苯乙烯类化合物及其在用于预防和/或治疗中枢神经系统相关疾病中的应用
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516219A (ja) 1996-07-30 2000-12-05 リチャード バーンスタイン，ローレンス ケラチノサイト増殖を抑制する方法と組成物
US20050059733A1 (en) 1999-12-06 2005-03-17 Welichem Biotech, Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
JP2010532658A (ja) 2007-06-18 2010-10-14 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡の治療におけるｔａｃｅインヒビター
JP2014519855A (ja) 2011-06-27 2014-08-21 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規ｔｈ１７分化マーカーおよびその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
EP1248774B1 (en) 1999-12-06 2009-10-07 Welichem Biotech Inc. Polyhydroxystilbenes and stilbene oxides as antipsoriatic agents and protein kinase inhibitors
CA2501663A1 (en) * 2002-10-01 2004-04-15 Welichem Biotech Inc. Stilbene derivatives having an immune-modulating activity
US9308239B2 (en) * 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US20100003315A1 (en) * 2008-07-02 2010-01-07 Willeford Kenneth L Method and Composition for the Treatment of Skin Conditions
CN101531571B (zh) 2009-04-17 2013-03-20 河北科技大学 六次甲基四胺氧化合成二苯乙烯类化合物的方法
CN101633606B (zh) 2009-08-13 2014-08-27 河北科技大学 盐酸非均相氯代合成茋类化合物的方法
CN101648851B (zh) 2009-09-03 2012-10-10 河北科技大学 (e)-3,5-二羟基-4-异丙基二苯乙烯的清洁制备方法
CN101830764A (zh) 2010-05-05 2010-09-15 河北科技大学 利用Pfitzner-moffatt氧化反应合成茋类化合物的方法
CN101838173A (zh) 2010-05-07 2010-09-22 河北科技大学 利用Kornblum氧化反应合成茋类化合物的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516219A (ja) 1996-07-30 2000-12-05 リチャード バーンスタイン，ローレンス ケラチノサイト増殖を抑制する方法と組成物
US20050059733A1 (en) 1999-12-06 2005-03-17 Welichem Biotech, Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
JP2010532658A (ja) 2007-06-18 2010-10-14 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡の治療におけるｔａｃｅインヒビター
JP2014519855A (ja) 2011-06-27 2014-08-21 ガルデルマ・リサーチ・アンド・デヴェロップメント ざ瘡についての新規ｔｈ１７分化マーカーおよびその使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ａｄｖａｎｃｅｓ ｉｎ Ｐｓｏｒｉａｓｉｓ，［ｏｎｌｉｎｅ］，２０１４年 ８月２８日，［２０１９年８月１４日検索］，インターネット，＜ＵＲＬ：ｈｔｔｐｓ：／／ｗｗｗ．ａｍａｚｏｎ．ｃｏｍ／Ａｄｖａｎｃｅｓ－Ｐｓｏｒｉａｓｉｓ－Ｍｕｌｔｉｓｙｓｔｅｍｉｃ－Ｊｅｆｆｒｅｙ－Ｗｅｉｎｂｅｒｇ／ｄｐ／Ｂ００ＲＹＳＧＧＫ４＞
Ａｄｖａｎｃｅｓ ｉｎ Ｐｓｏｒｉａｓｉｓ，２０１４年，ｐ．２２３ ［ＷＢＩ－１００１；Ｗｅｉｌｃｈｅｍ Ｂｉｏｔｅｃｈ；Ｉｎｃ．］
Ｂｒｉｔｉｓｈ Ｊｏｕｒｎａｌ ｏｆ Ｄｅｒｍａｔｏｌｏｇｙ，２０１２年，Ｖｏｌ．１６６， Ｎｏ．４，ｐｐ．８５３－８６０
ＰＬＯＳ ＯＮＥ，２０１４年 ８月，Ｖｏｌ．９， Ｎｏ．８ ，ｅ１０５２３８
日皮会誌、２００８年、Ｖｏｌ．１１８、Ｎｏ．１０、１８９３～１９２３頁

Also Published As

Publication number Publication date
DK3229840T5 (da) 2020-11-16
AU2015358910A1 (en) 2017-06-29
AU2015358910B2 (en) 2019-01-24
JP2021152018A (ja) 2021-09-30
WO2016092493A1 (en) 2016-06-16
JP2017537936A (ja) 2017-12-21
DK3229840T3 (da) 2020-11-09
KR20170095928A (ko) 2017-08-23
TW201639548A (zh) 2016-11-16
CA2970739C (en) 2023-10-03
CA2970739A1 (en) 2016-06-16
TWI692357B (zh) 2020-05-01
EP3229840A1 (en) 2017-10-18
US10376475B2 (en) 2019-08-13
AR102973A1 (es) 2017-04-05
ES2829637T3 (es) 2021-06-01
JP2023123554A (ja) 2023-09-05
US20170360719A1 (en) 2017-12-21
EP3229840B1 (en) 2020-09-09
KR102607222B1 (ko) 2023-11-29

Similar Documents

Publication Publication Date Title
JP7313117B2 (ja) 新規な使用方法
Demessant‐Flavigny et al. Skin microbiome dysbiosis and the role of Staphylococcus aureus in atopic dermatitis in adults and children: A narrative review
Han et al. The antimicrobial effect of CEN1HC-Br against Propionibacterium acnes and its therapeutic and anti-inflammatory effects on acne vulgaris
US20220273595A1 (en) Compositions and methods for treating eczema
Wang et al. Genistein suppresses psoriasis-related inflammation through a STAT3–NF-κB-dependent mechanism in keratinocytes
Bitschar et al. Staphylococcus aureus skin colonization is enhanced by the interaction of neutrophil extracellular traps with keratinocytes
JP6944399B2 (ja) プロバイオティクス細菌
Gasse et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis
Téllez-Pérez et al. Cholecalciferol (vitamin D) differentially regulates antimicrobial peptide expression in bovine mammary epithelial cells: implications during Staphylococcus aureus internalization
GB2542797A (en) Use of cannabinoids in the treatment of inflammatory skin diseases
WO2007011606A2 (en) USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
JP2012531448A (ja) 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
CN114080230A (zh) 氧化低渗酸溶液的治疗用途
Seneschal et al. Alopecia areata: Recent advances and emerging therapies
Schilter et al. The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-β1 pathway in human lung fibroblasts
Fang et al. LPS restores protective immunity in macrophages against Mycobacterium tuberculosis via autophagy
CN115551536A (zh) 用于增强损伤修复以及治疗细菌和病毒感染的胱天蛋白酶抑制剂
JP2002212100A (ja) ニキビ予防及び治療用スフィンゴ脂質組成物
CN109963594A (zh) 治疗皮肤病症的包含噻唑和开环甾类化合物的组合疗法
Tran Effect of Oxyresveratrol on Inflammatory Skin Diseases||
Farfán Esquivel Interaction between Cutibacterium acnes, bacteriophages and keratinocytes as a study model of acne phage therapy
US20180185391A1 (en) Drug Treatment Of Psoriasis And Of Other Skin Disorders Associated With Inhibition Of Differentiation Of Epidermal Cells
JP2016510809A (ja) 膣感染症の治療に使用するためのリファキシミン
Helwa The Mechanism of monomethylfumarate as an anti-psoriatic agent
Saleh Sequential peeling as a monotherapy for treatment of milder forms of acne vulgaris

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210122

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210521

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20210604

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210604

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210903

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220708

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230711

R150 Certificate of patent or registration of utility model

Ref document number: 7313117

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150